Intermediate Uveitis Drugs Pipeline Landscape Report 2021 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Intermediate Uveitis (Ophthalmology) – Drugs in Development, 2021” report has been added to ResearchAndMarkets.com’s offering.

The report provides comprehensive information on the therapeutics under development for Intermediate Uveitis, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.

The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Intermediate Uveitis and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The report provides a snapshot of the Global Therapeutic Landscape of Intermediate Uveitis (Ophthalmology).
• The report reviews pipeline therapeutics for Intermediate Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The report covers pipeline products based on various stages of development ranging from discovery till pre-registration.
• The report features descriptive drug profiles for the pipeline products which includes, Product Description, Descriptive MoA, R&D Brief, Licensing and Collaboration details & Other Developmental Activities.
• The report reviews key players involved in the development of Intermediate Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
• The report assesses Intermediate Uveitis (Ophthalmology) therapeutics based on Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
• The report summarizes all the dormant and discontinued pipeline projects.
• The report reviews latest news related to pipeline therapeutics for Intermediate Uveitis (Ophthalmology).

Key Topics Covered:

• Introduction
• Report Coverage
• Indication – Overview
• Indication – Therapeutics Development
• Pipeline Overview
• Pipeline by Companies
• Pipeline by Universities/Institutes
• Products under Development by Companies
• Products under Development by Universities/Institutes
• Indication – Therapeutics Assessment
• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Indication – Companies Involved in Therapeutics Development
• Indication – Drug Profiles
• Product Description
• Mechanism of Action
• R&D Progress
• Indication – Dormant Projects
• Indication – Discontinued Products
• Indication – Product Development Milestones
• Featured News & Press Releases
• Appendix

For more information about this report visit https://www.researchandmarkets.com/r/cn7zy6

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900